Skip to main content
Resources
  1. Home
  2. Resources

HNCIG provides a range of scientific resources to support researchers and clinicians involved in head and neck cancer research.

These include:

  • International consensus guidelines
  • Harmonised clinical trial datasets
  • Methodological frameworks for international studies
  • Publications from collaborative research projects.

Recent work includes the development of minimum datasets for head and neck cancer clinical trials and research, supporting global data harmonisation.

 
Search Clear

Programme for HNCIG Annual Meeting 2026
  • Publication

HNCIG Annual Meeting 2026 - 26th August in Brisbane, Australia

Publication of an international guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma
  • Consensus Documents
  • Guidelines
  • Publication

Members of the intergroup recently published an important guideline for delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. The article appears in Radiother Oncol. 2017 Nov 15 (DOI: 10.1016/j.radonc.2017.10.032).

HNCIG-endorsed consensus recommendations for postoperative radiotherapy in HNSCC in the presence of flaps
  • Consensus Documents
  • Publication

Head and neck reconstructive surgery using a flap is increasingly common. Best practices and outcomes for postoperative radiotherapy (poRT) with flaps have not been specified. We aimed to provide consensus recommendations to assist clinical decision-making highlighting areas of uncertainty in the presence of flaps.

HNCIG consensus recommendations for diagnosing extranodal extension on imaging
  • Consensus Documents
  • Publication

HNCIG conducted a five-round modified Delphi process with a group of 18 international radiology experts, representing 14 national clinical research groups. We generated consensus recommendations on the terminology and diagnostic criteria for imaging detected extranodal extension to harmonise clinical practice and research. These recommendations have been endorsed by 19 national and international organisations, representing 34 countries.

HNCIG consensus on endpoint definitions in recurrent and metastatic HNSCC trials
  • Consensus Documents
  • Publication

HNCIG assessed endpoint definitions from phase 3 trials or trials considered practice-changing for patients with recurrent or metastatic mucosal head and neck squamous cell carcinoma, published between 2008 and 2021.

HNCIG consensus guidelines for diagnosing pathologic extranodal extension
  • Consensus Documents
  • Guidelines
  • Publication

HNCIG conducted a three-round modified Delphi process with a group of 19 international pathology experts representing 15 national clinical research groups to generate consensus recommendations for histology detected extranodal extension diagnostic criteria.

HNCIG Consensus on Endpoint Definitions in Curative-intent Trials for HNSCC Published in Lancet Oncology
  • Consensus Documents
  • Publication

Robust time-to-event endpoint definitions are crucial for the assessment of treatment effect and the clinical value of trial interventions. Here, the Head and Neck Cancer International Group investigated endpoint use in phase 3 trials and trials considered potentially practice-changing published between 2008 and 2021 in the curative-intent setting for patients with mucosal head and neck squamous cell carcinoma. Of the 92 trials reviewed, we show that all core components of endpoint reporting were heterogeneous, including definitions of common terms, such as overall survival and progression-free survival. Our report highlights the urgent need for harmonisation of fundamental components of clinical trial endpoints and the engagement of all stakeholders to ensure the transparent reporting of endpoint details

Essential data variables for a minimum dataset for H&N cancer trails and research
  • Consensus Documents
  • HNCIG Database
  • Publication

HNCIG conducted a five-round modified Delphi process with a group of 18 international radiology experts, representing 14 national clinical research groups. We generated consensus recommendations on the terminology and diagnostic criteria for imaging detected extranodal extension to harmonise clinical practice and research. These recommendations have been endorsed by 19 national and international organisations, representing 34 countries. We propose a new classification system to aid diagnosis, which was supported by most of the participating experts over existing systems, and which will require validation in the future. Additionally, we have created an online educational resource for grading imaging detected extranodal extensions.

HNCIG-EPIC-OPC: Prognostic implications of P16 and HPV discordance: A multinational analysis
  • Publication

Report published in Lancet Oncology.

HNCIG-epic-opc: prognostic implications of P16 and HPV discordance: a multinational analysis, published in Lancet Oncology
  • Publication

p16INK4a (p16) immunohistochemistry is the most widely used biomarker assay for inferring HPV causation in oropharyngeal cancer in clinical and trial settings. However, discordance exists between p16 and HPV DNA or RNA status in some patients with oropharyngeal cancer. We aimed to clearly quantify the extent of discordance, and its prognostic implications.